Anderson J L, Pratt C M, Waldo A L, Karagounis L A
University of Utah, Salt Lake City 84143, USA.
Am J Cardiol. 1997 Jan 1;79(1):43-7. doi: 10.1016/s0002-9149(96)00673-x.
In his book Deadly Medicine and on television, Thomas Moore impugns the process of antiarrhythmic drug approval in the 1980s, alleging that the new generation of drugs had flooded the marketplace and had caused deaths in numbers comparable to lives lost during war. To assess these important public health allegations, we evaluated annual coronary artery disease death rates in relation to antiarrhythmic drug sales (2 independent marketing surveys). Predicted mortality rates were modeled using linear regression analysis for 1982 through 1991. Deviations from predicted linearity were sought in relation to rising and falling class IC and overall class I antiarrhythmic drug use. Flecainide came to market in 1986 and encainide in 1987. Combined class IC sales peaked in 1987 and 1988 (maximum market penetration, 20%, first quarter 1989). Results of the Cardiac Arrhythmia Suppression Trial (CAST) were disclosed in April 1989. Overall annual class I antiarrhythmic prescription sales actually fell slightly (-3% to -4%/yr) in the 2 years before CAST and then more abruptly (- 12%) in the year after CAST (1990). Sales of class IC drugs fell dramatically after CAST (by 75%). Coronary death rates (age adjusted) fell in a linear fashion during the decade of 1982 through 1991. No deviation from predicted rates was observed during the introduction, rise, and fall in class IC (and other class I) sales: rates were 126/100,000 in 1985 (before flecainide), 114 and 110 in 1987 and 1988 (maximum sales), and 103 in 1990 (after CAST). Deviations in death rates in the postulated range of 6,000 to 25,000 per year were shown to be excluded easily by the 95% confidence intervals about the predicted rates. Entry of new antiarrhythmic drugs in the 1980s did not lead to overall market expansion and had no adverse impact on coronary artery disease death rates, which fell progressively. Thus, the allegations in Deadly Medicine could not be confirmed.
托马斯·摩尔在其著作《致命药物》及电视节目中,抨击了20世纪80年代抗心律失常药物的审批过程,称新一代药物充斥市场,导致的死亡人数堪比战争中的死亡人数。为评估这些重要的公共卫生指控,我们评估了与抗心律失常药物销售相关的年度冠状动脉疾病死亡率(两项独立的市场调查)。使用线性回归分析对1982年至1991年的预测死亡率进行建模。针对I类C组及I类抗心律失常药物总体使用量的增减,探寻与预测线性的偏差。氟卡尼于1986年上市,恩卡尼于1987年上市。I类C组合并销售额在1987年和1988年达到峰值(最大市场渗透率,20%,1989年第一季度)。心律失常抑制试验(CAST)的结果于1989年4月公布。在CAST之前的两年里,I类抗心律失常药物的总体年度处方销售额实际上略有下降(每年-3%至-4%),在CAST之后的一年(1990年)下降更为突然(-12%)。CAST之后,I类C组药物的销售额大幅下降(75%)。在1982年至1991年的十年间,冠状动脉疾病死亡率(年龄调整后)呈线性下降。在I类C组(及其他I类)药物销售的引入、上升和下降期间,未观察到与预测死亡率的偏差:1985年(氟卡尼上市前)为126/10万,1987年和1988年(销售额最高时)为114和110,1990年(CAST之后)为103。每年假定的6000至25000例死亡率偏差很容易被预测死亡率的95%置信区间排除。20世纪80年代新型抗心律失常药物的进入并未导致市场总体扩张,对冠状动脉疾病死亡率也没有不利影响,死亡率呈逐渐下降趋势。因此,《致命药物》中的指控无法得到证实。